We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
As a result of a GBP3.5mn (US$6.31mn) cut in government funding, the UK's National Institute for Health and Clinical Excellence (NICE) has had to close one of its three appraisal committees.
Shire Pharmaceuticals Group PLC said Canadian regulators have allowed it to resume marketing of hyperactivity treatment Adderall XR, the company's biggest product, following the drug's withdrawal in February amid safety concerns.
Drug-maker Ind Swift Laboratories Ltd today said it has received the approval from the Drug Controller General of India (DCGI) for its newly-developed anti-diarrhoea plus anti-bacterial drug and also announced its plans to launch the combination next month.
Callisto Pharmaceuticals, Inc. (AMEX:KAL), a developer of novel drug therapies in the fight against hematologic cancers and related diseases, announced today completion of a private placement financing of approximately 1.87 million shares of common stock at a per-share price of $0.97 for aggregate gross proceeds of approximately $1.8 million.
Biotechnology firm Biocon Ltd. said on Tuesday it has tied up with U.S.-based Nobex Corporation to develop an oral peptide product to treat cardiovascular diseases.